OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models. METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal. Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types. After 1-2 months, grafts were retrieved for comparison with original tissues. Hematoxylin and eosin (H&E) and immunohistochemical staining was carried out using tissue micro-arrays and CEA, B72.3, WT-1, OC125, keratin, inhibin, CK7, CK20, Cam5.2, and MIB-1 as markers. RESULTS: Tumor tissue engraftment rate was > 95%. Comparison of donor and post-graft tissues showed highly similar histopathological features; 91 +/- 5% concordance in immunostaining indicated major preservation of immunophenotypes in the xenografts for 30-60 days. There was a small, but significant, increase in MIB-1 proliferative index in xenografts compared to original specimens. CONCLUSIONS: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues. The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms. Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models. METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCIDmice within 2 h of surgical removal. Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types. After 1-2 months, grafts were retrieved for comparison with original tissues. Hematoxylin and eosin (H&E) and immunohistochemical staining was carried out using tissue micro-arrays and CEA, B72.3, WT-1, OC125, keratin, inhibin, CK7, CK20, Cam5.2, and MIB-1 as markers. RESULTS:Tumor tissue engraftment rate was > 95%. Comparison of donor and post-graft tissues showed highly similar histopathological features; 91 +/- 5% concordance in immunostaining indicated major preservation of immunophenotypes in the xenografts for 30-60 days. There was a small, but significant, increase in MIB-1 proliferative index in xenografts compared to original specimens. CONCLUSIONS: Subrenal capsule xenografts of primary humanovarian tumors in SCIDmice can retain major histopathological and immunohistochemical characteristics of the original tissues. The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms. Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
Authors: S John Weroha; Marc A Becker; Sergio Enderica-Gonzalez; Sean C Harrington; Ann L Oberg; Matthew J Maurer; Sarah E Perkins; Mariam AlHilli; Kristina A Butler; Sarah McKinstry; Stephanie Fink; Robert B Jenkins; Xiaonan Hou; Kimberly R Kalli; Karin M Goodman; Jann N Sarkaria; Beth Y Karlan; Amanika Kumar; Scott H Kaufmann; Lynn C Hartmann; Paul Haluska Journal: Clin Cancer Res Date: 2014-01-07 Impact factor: 12.531
Authors: E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack Journal: Oncogene Date: 2013-08-12 Impact factor: 9.867
Authors: Monique D Topp; Lynne Hartley; Michele Cook; Valerie Heong; Emma Boehm; Lauren McShane; Jan Pyman; Orla McNally; Sumitra Ananda; Marisol Harrell; Dariush Etemadmoghadam; Laura Galletta; Kathryn Alsop; Gillian Mitchell; Stephen B Fox; Jeffrey B Kerr; Karla J Hutt; Scott H Kaufmann; Elizabeth M Swisher; David D Bowtell; Matthew J Wakefield; Clare L Scott Journal: Mol Oncol Date: 2014-01-24 Impact factor: 6.603
Authors: Erin George; Hyoung Kim; Clemens Krepler; Brandon Wenz; Mehran Makvandi; Janos L Tanyi; Eric Brown; Rugang Zhang; Patricia Brafford; Stephanie Jean; Robert H Mach; Yiling Lu; Gordon B Mills; Meenhard Herlyn; Mark Morgan; Xiaochen Zhang; Robert Soslow; Ronny Drapkin; Neil Johnson; Ying Zheng; George Cotsarelis; Katherine L Nathanson; Fiona Simpkins Journal: JCI Insight Date: 2017-01-12
Authors: Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland Journal: Clin Cancer Res Date: 2012-08-15 Impact factor: 12.531
Authors: Vincent C Daniel; Luigi Marchionni; Jared S Hierman; Jonathan T Rhodes; Wendy L Devereux; Charles M Rudin; Rex Yung; Giovanni Parmigiani; Marion Dorsch; Craig D Peacock; D Neil Watkins Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701
Authors: Bjoern Chapuy; Hongwei Cheng; Akira Watahiki; Matthew D Ducar; Yuxiang Tan; Linfeng Chen; Margaretha G M Roemer; Jing Ouyang; Amanda L Christie; Liye Zhang; Daniel Gusenleitner; Ryan P Abo; Pedro Farinha; Frederike von Bonin; Aaron R Thorner; Heather H Sun; Randy D Gascoyne; Geraldine S Pinkus; Paul van Hummelen; Gerald G Wulf; Jon C Aster; David M Weinstock; Stefano Monti; Scott J Rodig; Yuzhuo Wang; Margaret A Shipp Journal: Blood Date: 2016-01-15 Impact factor: 22.113